Citadel Advisors’s Exagen XGN Stock Holding History

Citadel Advisors’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.9K	Sell	14,393 -216,722	-94%	-$816K	﹤0.01%	12966
2026 Q1	$693K	Buy	231,115 +42,657	+23%	+$165K	﹤0.01%	8512
2025 Q4	$1.15M	Buy	188,458 +72,228	+62%	+$657K	﹤0.01%	7086
2025 Q3	$1.28M	Buy	+116,230	New	+$1.03M	﹤0.01%	7013
2025 Q2	–	Sell	-4,284	Closed	-$15.4K	–	15396
2025 Q1	$15.4K	Sell	4,284 -18,065	-81%	-$68.2K	﹤0.01%	13322
2024 Q4	$91.6K	Sell	22,349 -660	-3%	-$2.38K	﹤0.01%	11609
2024 Q3	$71.1K	Sell	23,009 -2,370	-9%	-$6.14K	﹤0.01%	11537
2024 Q2	$46.2K	Buy	25,379 +18,139	+251%	+$30.7K	﹤0.01%	11852
2024 Q1	$11.5K	Sell	7,240 -13,495	-65%	-$26.2K	﹤0.01%	13406
2023 Q4	$41.3K	Buy	+20,735	New	+$35.9K	﹤0.01%	11985
2022 Q3	–	Sell	-27,996	Closed	-$156K	–	13739
2022 Q2	$160K	Buy	+27,996	New	+$163K	﹤0.01%	10922

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Citadel Advisors's XGN Position: Q2 2026 in Review

Citadel Advisors reduced its Exagen (XGN) stake by 94% in Q2 2026, selling an estimated $816K and leaving 14,393 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12966.

Citadel Advisors first reported a position in XGN in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.28M in Q3 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Citadel Advisors held 14,393 shares of Exagen worth $66.9K as of Q2 2026.
Citadel Advisors sold 216,722 Exagen shares in Q2 2026, an estimated $816K.
Exagen made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12966 holding.
Citadel Advisors first reported a position in Exagen in Q2 2022 and has held it in 11 quarters since.
Citadel Advisors's Exagen position peaked at $1.28M in Q3 2025.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.